On the stock market since 2020, it operates in the world of health and science. It has 184 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 13% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 9% a year on average.
Sales run at $2.0M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 18 buys and 8 sells. Management buying with its own money is usually read as a good sign.
A loss of $40.8M against $2.0M in annual sales.
The stock sits at $0.0090. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, HUMAW sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HUMAW is a high-risk stock — not yet profitable, and its future rides on its product catching on.